Dabrafenib
Back to searchMolecule Structure
Scientific Name
Dabrafenib
Description of the Drug
Dabrafenib is a kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08912
http://www.drugbank.ca/drugs/DB08912
Brand Name(s)
Tafinlar
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Serine/threonine-protein kinase B-raf | SINGLE PROTEIN | INHIBITOR | CHEMBL5145 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL806377 | ||
| Human Metabolome Database | HMDB0250818 | ||
| DrugBank | DB08912 | ||
| PubChem: Thomson Pharma | 85742096 | ||
| PubChem | 44462760 | ||
| LINCS | LSM-6303 | ||
| Nikkaji | J3.135.454D | ||
| PDBe | P06 | ||
| BindingDB | 50428286 | ||
| EPA CompTox Dashboard | DTXSID20152499 | ||
| DrugCentral | 4801 | ||
| Brenda | 247461 | ||
| ChemicalBook | CB32604230 | ||
| Guide to Pharmacology | 6494 | ||
| rxnorm | DABRAFENIB MESYLATE | DABRAFENIB | TAFINLAR |
| ChEBI | 75045 | ||
| ZINC | ZINC000068153186 |
